EUVIMEDAtklāt EUVIMED
Open access · CC BY 4.0

Early Post‐Kidney Transplant Treatment With Roxadustat Ameliorates Anemia and Reduces Blood Transfusion Needs in Inflamed Patients: A Case‐Matched Study

Paolo Randone, Laura Valenza, Alberto Mella, Fabrizio Fop, Caterina Dolla, Ester Gallo, Ana Maria Manzione, Silvia Mingozzi, Rita Tarragoni, Enrico Sanna, Luigi Biancone iD

Clinical Transplantation · 2026-07 · 40 (7)

DOI: 10.1111/ctr.70617 ↗

At a glance

Journal article in Clinical Transplantation, published online on 2026-07-08. Written by Paolo Randone and 10 co-authors. Institution: Renal Transplant Center "A. Vercellone", Nephrology, Dialysis and Renal Transplant Division, Department of Medical Sciences, "Città Della Salute e de…. Major MEDLINE topics: Kidney Transplantation, Glycine, Isoquinolines, Anemia. 28 references. The full text is freely available (open access, CC BY 4.0). Funded by: University of Turin, Università degli Studi di Torino.

AbstraktsSubjectsBibliogrāfiskie datiCiteRelated studies

Abstract (original language)

Background

Roxadustat is an oral hypoxia‐inducible factor prolyl‐hydroxylase inhibitor. Recent studies have shown no inferiority of roxadustat compared to erythropoietin in chronic kidney disease and in post‐transplant patients. We evaluated roxadustat versus erythropoiesis‐stimulating agents (ESAs) in very early posttransplant patients.

Methods

We performed a retrospective analysis of the clinical course and laboratory changes in posttransplant patients treated with roxadustat (16 patients) or a high‐dose erythropoiesis‐stimulating agent (ESA) (16 patients) for anemia between March and September 2025. We compared haemoglobin, creatinine, lipid levels, and iron status. The therapy was started after the kidney transplant, respectively, after a median of 3.5 and two days. Every patient was followed up at two weeks, one month, two months, and three months.

Results

Patients treated with roxadustat showed a significantly greater and faster increase in Hb levels at 2 weeks ( p = 0.047) than the ESA group. After 2 weeks, we observed a significant difference in the need for blood transfusions between the groups ( p = 0.029; 18.8% in the roxadustat group vs. 62.5% in the ESA group). No significant differences were observed in iron or inflammation status during the study. The roxadustat group achieved a significantly better lipid profile after one month ( p < 0.05 for cholesterol and LDL). During the follow‐up, no adverse events related to roxadustat were reported.

Conclusion

Administration of oral roxadustat in very early post‐transplant patients is effective and safe, rapidly improving anemia and reducing the need for transfusions.

Subjects

MeSH terms (MEDLINE)

Kidney TransplantationGlycineIsoquinolinesAnemiaBlood TransfusionInflammationPostoperative ComplicationsKidney Failure, ChronicHumansFemaleRetrospective StudiesMaleFollow-Up StudiesMiddle AgedPrognosisHematinicsCase-Control StudiesAdultRisk FactorsKidney Function TestsGlomerular Filtration Rate

Author keywords

blood transfusionerythropoiesis‐stimulating agentspost‐transplant anemiaroxadustat

Substances

roxadustatGlycineIsoquinolinesHematinics

Authors and institutions

  • Renal Transplant Center "A. Vercellone", Nephrology, Dialysis and Renal Transplant Division, Department of Medical Sciences, "Città Della Salute e della Scienza" Hospital, University of Turin, Turin, Italy.

ORCID profiles: Luigi Biancone

Funding

  • University of Turin
  • Università degli Studi di Torino

Cite

APA

Randone, P., Valenza, L., Mella, A., Fop, F., Dolla, C., Gallo, E., Manzione, A. M., Mingozzi, S., Tarragoni, R., Sanna, E., & Biancone, L. (2026). Early Post‐Kidney Transplant Treatment With Roxadustat Ameliorates Anemia and Reduces Blood Transfusion Needs in Inflamed Patients: A Case‐Matched Study. Clinical Transplantation, 40(7). https://doi.org/10.1111/ctr.70617

Vancouver

Randone P, Valenza L, Mella A, Fop F, Dolla C, Gallo E, et al. Early Post‐Kidney Transplant Treatment With Roxadustat Ameliorates Anemia and Reduces Blood Transfusion Needs in Inflamed Patients: A Case‐Matched Study. Clinical Transplantation. 2026;40(7). doi:10.1111/ctr.70617

BibTeX
@article{Randone2026,
  author = {Randone, Paolo and Valenza, Laura and Mella, Alberto and Fop, Fabrizio and Dolla, Caterina and Gallo, Ester and Manzione, Ana Maria and Mingozzi, Silvia and Tarragoni, Rita and Sanna, Enrico and Biancone, Luigi},
  title = {Early Post‐Kidney Transplant Treatment With Roxadustat Ameliorates Anemia and Reduces Blood Transfusion Needs in Inflamed Patients: A Case‐Matched Study},
  journal = {Clinical Transplantation},
  year = {2026},
  volume = {40},
  number = {7},
  doi = {10.1111/ctr.70617}
}
Start for free →